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risk of breast cancer recurrence and mortality, while considering
the side effect proﬁle of the treatment. METHODS: A total of
85 women aged 50–83 (mean 61) years were recruited from the
Australian general public. Participants completed questions
regarding breast cancer experience and undertook a discrete
choice task. The attributes used in the WTP scenarios included
values for risk of breast cancer recurrence, mortality, hot ﬂushes,
vaginal abnormalities, deep vein thrombosis (DVT) and fracture,
and also cost. The risk estimates against placebo were derived
using indirect comparisons. RESULTS: A total of 74 subjects
provided evaluable data. Eleven subjects were excluded because
they were non-traders (3) or irrational in their choice task. The
total WTP for anastrozole over placebo was AUS$906.00 per
month (95% CI: 380.7–1548.7) for 4–5 years. This included a
WTP of AUS$794.20, AUS$481.70, AUS$38.20 and AUS$32.10
for the reduced risk of breast cancer recurrence, mortality, 
hot ﬂushes and vaginal abnormalities, respectively. For DVT 
and fracture, which favoured placebo, negative WTPs of 
-AUS$316.00 and -AUS$124.20, respectively, were obtained.
CONCLUSIONS: Subjects were willing to pay an average of
AUS$906.00 per month for 4–5 years for access to a treatment
with the attributes of anastrozole. The reduced risk of breast
cancer recurrence and mortality were the main drivers for the
treatment; however, increased risk of fracture and DVT were also
of concern to participants.
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OBJECTIVES: To document and compare actual treatment prac-
tices, outcomes (hematopoietic response rates, Hb changes,
transfusions, hospital care), and health care costs of Epoetin alfa
and Darbepoetin alfa in the treatment of chemotherapy-related
anemia in cancer patients in Sweden. METHODS: A retrospec-
tive chart review was performed at 3 Swedish hospitals. A total
of 59 patients with cancer who developed chemotherapy-related
anemia and received erythropoiesis-stimulating agent treatment
were identiﬁed: 29 patients initially received epoetin alfa and 30
patients initially received darbepoetin alfa. Data were collected
on dosage and duration of treatment with these agents, hemo-
globin (Hb) response measures, red blood cell transfusions, and
health care resource consumption and analyzed at follow-up
time points of 28, 56, 84, and 112 days. RESULTS: A signiﬁ-
cantly faster Hb response and increase in Hb levels was observed
in patients treated with eEpoetin alfa compared to patients
treated with Darbepoetin alfa. Lower dosages are used in actual
clinical practice than recommended in Swedish treatment guide-
lines. No signiﬁcant differences in resource utilization or in
health care costs between epoetin alfa- or darbepoetin alfa-
treated patients were found. At a follow-up of 112 days, the
mean treatment cost per patient was SEK74,701 (approximately
US$9800 or 8300€) with epoetin alfa and SEK85,285 (approx-
imately US$11,000 or 9500€) with darbepoetin alfa. Drug acqui-
sition and administration costs accounted for 81% and 67% of
total costs for epoetin alfa- and darbepoetin alfa-treated patients,
respectively, with remaining costs accounted for by hospitaliza-
tion and transfusions. CONCLUSIONS: Epoetin alfa was asso-
ciated with a signiﬁcantly faster Hb response, and signiﬁcantly
higher increases in Hb levels compared with darbepoetin alfa, as
used clinically. While the costs are in favor of epoetin alfa, they
are not signiﬁcantly different for the two treatment arms. Lower
dosages of both agents are used in actual clinical practice than
recommended in Swedish treatment guidelines.
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OBJECTIVES: To systematically evaluate the impact of screen-
ing adherence on clinical effectiveness and cost-effectiveness of
cervical cancer screening (CCS) in Germany using a decision ana-
lytic approach. METHODS: A decision-analytic Markov model
was used to evaluate long-term clinical and economic outcomes
for the following CCS strategies: 1) no screening; 2) conventional
Papanicolaou test with manual smear analysis (PAP); 3) PAP
with automated smear analysis (AA); 4) liquid-based preparation
(LP) with manual smear analysis; and 5) LP in combination with
AA. German clinical, epidemiological and economic data were
used. German clinical practice in screening, diagnosis, and treat-
ment of cervical cancer and its precursors were considered. Cal-
culated outcomes were detected/prevented cervical cancer cases
and deaths, life expectancy, lifetime costs, and discounted incre-
mental cost-effectiveness ratios (ICER). We adopted a societal
perspective with a three percent (3%) annual discount rate. In
the absence of individual data, screening adherence was modeled
to be independent from screening history. RESULTS: In women
adherent to screening, annual PAP saved 94 life days, when com-
pared to “no screening”, and new CCS strategies saved addi-
tional 0.5 days. Assuming 50% adherence annual screening with
new strategies would save additional 3 days compared to annual
PAP screening with 50% adherence and would be nearly equally
effective as annual PAP with complete adherence. Assuming a
societal willingness-to-pay of 50,000€/LYS, annual PAP com-
pared to “no screening” was cost-effective independent of
screening adherence. Annual screening with new strategies com-
pared to PAP was not cost-effective in adherent women, but may
be cost-effective with 65% (AA) or 40% (LP or LP + AA) or
lower adherence. CONCLUSIONS: For the current clinical stan-
dard of annual cervical cancer screening in Germany, PAP screen-
ing is both medical effective and cost-effective independent of
adherence. New CCS strategies may be effective and cost-
effective in women who do not regularly attend annual screen-
ing programs.
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OBJECTIVES: Develop and categorise pharmaceutical care
activities that contribute to the care of patients receiving cancer
chemotherapy. METHODS: A retrospective survey of clinical
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records of pharmacists at six Scottish cancer treatment centres
and units was undertaken where a standardised care plan (Mac-
intyre et al. Development of a system for reporting pharmaceu-
tical care issues in cancer patients receiving chemotherapy.
Pharm J 2003;271:266–7) was utilised. Records were entered
into an electronic version of the care plan and activities were
recorded according to deﬁnitions by McAnaw (McAnaw JJ.
Development of novel approaches to demonstrate the quality of
drug therapy use. PhD thesis. Glasgow: University of Strathclyde.
2003). Categorisation system for pharmaceutical care issues was
utilised and its reliability was assessed with Cohen’s Kappa.
RESULTS: A total of 2737 pharmaceutical care issues were
recorded from 729 patients receiving 3376 cycles of chemother-
apy (0.8 care issues per cycle), 2711 care issues were categorised
into Drug Therapy Problems (DTP’s) as deﬁned by Cipolle et al.
(Cipolle RJ et al. Identifying, resolving, and preventing drug
therapy problems: the pharmacist’s responsibility. In: Pharma-
ceutical Care Practice. New York: McGraw-Hill. 1998). Relia-
bility of the categorisation assessed with Cohen’s Kappa was
found to be at least “good” (Kappa between 0.60 and 0.75) in
all but one categories tested. The most common DTP addressed
was “adverse drug reaction” (77%). Others included “dose too
high/dose too low” (9%) and “additional medication needs”
(8%). Care issues were also categorised as “checks” (67%) or
“changes” (33%). Checks were mainly “veriﬁcations” prior to
administration (75%) rather than ongoing “monitoring” (25%).
Changes were “modiﬁcations” (49%), individualised “adjust-
ments” (38%) or “prompted revisions” of the treatment (13%).
CONCLUSIONS: Results show the system’s potential to
promote standardised documentation of pharmaceutical care
delivered to patients undergoing cancer chemotherapy as an
important contribution to quality assurance in cancer
chemotherapy.
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OBJECTIVES: Cancer is the second leading cause of death in the
United States and a major contributor to health care expendi-
tures. Our objective was to investigate whether disparities in 
outpatient treatment costs exist among an economically homoge-
nous group—those on Medicaid. METHODS: Utilizing Mary-
land Medicaid administrative claims data, a retrospective cohort
design was employed to examine disparities in ambulatory treat-
ment costs of breast, colorectal and prostate cancer treatments
by region, race and gender. We report mean and median results
by each demographic category and test for the statistical signif-
icance of each. Lorenz curves are plotted and Gini coefﬁcients
calculated for each type of cancer. RESULTS: We do not ﬁnd a
consistent trend in ambulatory costs across the 3 cancers by tra-
ditional demographic variables. Lorenz curves indicate highly
unequal distributions of costs. Gini coefﬁcients are 0.687 for
breast cancer, 0.757 for colorectal cancer, and 0.774 for prostate
cancer. CONCLUSIONS: Signiﬁcant variation in non-hospital
based expenditures exists for breast, colorectal and prostate
cancers in a population of homogeneous socio-economic status
and uniform insurance entitlement. Observed individual level
disparities are not consistent across cancers by region, race or
gender, but the majority of this low income population receives
very little ambulatory care.
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OBJECTIVES: To assess patient outcomes of various strategies
for determining diagnosis and resectability in patients with sus-
pected pancreatic cancer (PC). METHODS: We used data from
a prospective study of 193 patients with suspected PC performed
at the Charité University Hospital from August, 1999–Novem-
ber, 2000. These patients underwent each of the following six
different diagnostic procedures: ultrasound (US), magnetic reso-
nance imaging (MR), computed tomography (CT), endoscopic
ultrasound (EUS), ﬂuorodeoxyglucose positron emissiontomog-
raphy (PET), and endoscopic retrograde cholangiopancreaticog-
raphy (ERCP). We developed a decision tree to predict diagnostic
accuracy and resectability using the conditional probabilities
derived from our study. In the ﬁrst step, we sought to maximize
the number of patients having both diagnostic and resectability
state correctly classiﬁed. As the varying types of incorrect assess-
ments lead to different clinical consequences, we determined a
clinical consequence score to assess the impact of these conse-
quences on mortality and quality of life (e.g. inadequate treat-
ment following an imperfect classiﬁcation). This score ranged
from 100 (best scenario, benign diagnosed as benign) to 0 (worst
scenario, benign and unresectable classiﬁed as resectable). Each
possible scenario’s score was estimated by a clinical panel of
experts. In the second step, these score values were incorporated
into the decision tree as patient outcome weights. RESULTS:
Regarding correct classiﬁcation, best test performance was
achieved with MR alone, correctly classifying 79% of patients
as benign, malignant/resectable, or malignant/unresectable. The
combination of PET and EUS had the worst performance with
only 61% of patients correctly classiﬁed. The incorporation of
the clinical consequence score lead only to minor differences
between the strategies. Probabilistic sensitivity analysis showed
robust results in both portions of the study. CONCLUSIONS:
The incorporation of the clinical consequence score failed to
determine a superior strategy. Once quality-adjusted life years
and costs are estimated, we will perform a cost-effectiveness
analysis.
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OBJECTIVE: To use meta-analysis techniques to pool both clin-
ical effect and cost data to provide an absolute estimate of 
the likely survival and cost of BSC in advanced NSCLC.
METHODS: A systematic review of published clinical and eco-
nomic literature identiﬁed patient cohorts with stage IIIb and IV
NSCLC receiving BSC at any stage of treatment. Data on 12
month, 24 month and median survival, as well as cost of BSC,
were extracted from the original publications. With appropriate
ﬁxed and random effect meta-analysis techniques, data of com-
